In this article:

TCR2 Therapeutics (TCRR) Receives a Buy from Mizuho Securities

In this article:
In this article:

Mizuho Securities analyst Mara Goldstein maintained a Buy rating on TCR2 Therapeutics (TCRRResearch Report) today and set a price target of $20.00. The company’s shares closed last Tuesday at $4.56.

According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 14.0% and a 41.6% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Corvus Pharmaceuticals.

TCR2 Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $22.50.

See the top stocks recommended by analysts >>

The company has a one-year high of $35.10 and a one-year low of $4.57. Currently, TCR2 Therapeutics has an average volume of 821.2K.

Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TCRR in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

TCR2 Therapeutics, Inc. is an immunotherapy company, which develops biological drugs and engineering T-cells for cancer therapy. The company offers cancer therapy, T-cell biology, Immunology and Molecular biology. It also engages in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded in May 2015 and is headquartered in Cambridge, MA.

Read More on TCRR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed